Friday, April 18, 2014

Veteran banker Michael Mandel has joined Brean Capital

Veteran banker Michael Mandel has joined Brean Capital

April 16, 2014 by · Leave a Comment 

Tweet Brean Capital has recently hired veteran healthcare investment banker, Michael Mandel, as managing director of the firm based in New York. Mr. Mandel has over 17 years of experience in healthcare investment banking and has successfully closed over 60 financing and M&A transactions for private, large and small/mid cap public companies with aggregate transaction […]

Cynapsus completes $25-million financing

Cynapsus completes $25-million financing

April 15, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has completed the sale of 38,461,538 units at a price of 65 cents each for gross proceeds of $25-million.  Each unit consists of one common share and one warrant.  Each warrant can be exercised to purchase an additional common share during the next 60 months. The offering was led by M Partners […]

Aurinia to begin lupus nephritis trial in Q2

Aurinia to begin lupus nephritis trial in Q2

April 15, 2014 by · Leave a Comment 

Tweet Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient in the next few weeks in a Phase 2b clinical trial with its voclosporin immunosuppressant in combination with CellCept®, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “We are now well […]

Roth starts AcelRx Pharma at buy

Roth starts AcelRx Pharma at buy

April 14, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and $22 price target. The stock closed at $10.32 on Friday. “We believe Zalviso is a disruptive technology that will transform the way many hospitals treat patients with moderate-to-severe acute pain, primarily in the postoperative setting, by providing a solution demonstrated to […]

Leerink starts Kindred Biosciences at outperform

Leerink starts Kindred Biosciences at outperform

April 14, 2014 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Kindred Biosciences (NASDAQ:KIN) with an “outperform” rating and a $32 price target based on a forecast of discounted cash flow. The stock closed at $14.66 on Friday. Kindred is focused on bringing therapies for the treatment of dogs, cats, and horses to market. “With three products in pivotal […]

Leerink starts Ignyta at outperform

Leerink starts Ignyta at outperform

April 9, 2014 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Ignyta (NASDAQ:RXDX) with an “outperform” rating and $14 valuation. The stock is changing hands at $6.63 on Wednesday afternoon. Given many historical precedents, Ignyta’s targeted therapy in oncology has a “better than average chance of success despite that the lead compound RXDX-101 is still in early stage development,” […]

CombiMatrix names Sahoo head of cytogenetics

CombiMatrix names Sahoo head of cytogenetics

April 9, 2014 by · Leave a Comment 

Tweet CombiMatrix (NASDAQ:CBMX) has named Dr. Trilochan Sahoo as director of cytogenetics, reporting to CMO Dr. Wes Tyson. Dr. Sahoo was previously senior director, clinical cytogenetics, with Quest Diagnostics Nichols Institute in San Juan Capistrano, California. He has written more than 60 published research papers, most of them in the field of molecular cytogenetics, which […]

Avita Medical releases new version of ReCell

Avita Medical releases new version of ReCell

April 8, 2014 by · Leave a Comment 

Tweet Avita Medical (ASX:AVH; OTCQX:AVMXY) has developed and released a new version of ReCell “Spray-on Skin” that no longer requires refrigeration in order to improve the commercial and practical benefits to clinicians. The new version of ReCell has been cleared for use and is starting to be sold in the U.K. and Europe. Avita is […]

Roth ups Lion Biotechnologies target to $20

Roth ups Lion Biotechnologies target to $20

April 8, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” Lion Biotechnologies (OTC:LBIO) to $20 from $15, after Dr. Steven Rosenberg of the NCI presented Phase 2 data at the American Association of Cancer Research meeting from an ongoing Phase 2 study showing strong response rates from Lion’s tumor infiltrating lymphocyte (TIL) technology in […]

Transition updates drug development program

Transition updates drug development program

April 7, 2014 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has updated the development of its drug candidates and plans for future growth. In a statement, the company said the addition of the neuropsychiatric drug candidate ELND005 has broadened its development pipeline with an un-partnered, late-stage clinical asset, coupled with Transition’s core strategy of advancing assets acquired from pharmaceutical partners. […]

Next Page »

Google+